A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population Publication A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population CertaraNovember 7, 2024
Bioequivalence Analysis of Ondansetron Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Two-Period Crossover Phase I Study Publication Bioequivalence Analysis of Ondansetron Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Two-Period Crossover Phase I Study Explore how ondansetron formulations are bioequivalent under fasting and fed conditions, confirmed using Phoenix WinNonlin.CertaraOctober 29, 2024
Why you need an integrated development plan Blog Why you need an integrated development plan Learn about the Integrated Development Plan for successful drug development & its relation to the…CertaraOctober 17, 2024
Academic Centers of Excellence for Model-informed Drug Development (MIDD) Fact Sheet Academic Centers of Excellence for Model-informed Drug Development (MIDD) CertaraOctober 16, 2024
Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps Publication Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps CertaraOctober 16, 2024
16th Annual World ADC London 2026 Conference 16th Annual World ADC London 2026 CertaraOctober 11, 2024
Why cancer drug programs need human mass balance studies Blog Why cancer drug programs need human mass balance studies Historically, drug programs for oncology and other rapidly fatal diseases didn’t include mass balance studies…CertaraSeptember 23, 2024
A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule‑1 Biomarker Publication A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule‑1 Biomarker Discover how PK‑TD modelling shows palonosetron reduces platinum exposure and KIM‑1 elevations versus other antiemetics…CertaraSeptember 20, 2024
Intravenous Versus Intraosseous Use of Tranexamic Acid in Patients With Traumatic Brain Injury Publication Intravenous Versus Intraosseous Use of Tranexamic Acid in Patients With Traumatic Brain Injury See how IV and intraosseous TXA show similar total exposure in prehospital TBI care, analysed…CertaraSeptember 2, 2024